In our assessment of HER2 expression using the IHC method and PD-L1 expression using the combined positive score (CPS) in 451 GC samples, we found that neither HER2 nor PD-L1 expression levels significantly affected the overall survival (OS) of patients (Fig. 3A, B). Here, ERBB2 is linked to gastric cancer.